About the Company
ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products. The company was founded in 1993 and is headquartered in Burlington, MA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ARQL News
Merck buys ArQule and BTK drug for $2.7bn
Merck & Co. has announced it is to snap up ArQule for $2.7 billion, just as the US biotech announced new data from a blood cancer drug that could be used after rival therapies fail.
Merck Sharp & Dohme Corp.'s Net Worth
This is based on reported shares across multiple companies, which include OPGEN INC, BeiGene, Ltd., ARQULE INC, NGM BIOPHARMACEUTICALS INC, SUTRO BIOPHARMA INC, and Menlo Therapeutics Inc..
PFIZER INC's Net Worth
PFIZER INC has an estimated net worth of $2.44 Billion. This is based on reported shares across multiple companies, which include BioAtla, Inc., Viatris Inc, Cerevel Therapeutics Holdings, Inc ...
To battle B-cell cancers, drugmakers are going beyond the covalent bond
This molecule was first synthesized in 2012 by chemists at Daiichi Sankyo in collaboration with scientists at ArQule. But the molecule was not seen as a success, and Daiichi Sankyo returned it to ...
Hedge Fund - Biotechnology Value Fund / BVF Inc
Spero Therapeutics Inc (NASDAQ:SPRO): Mark Lampert's Biotechnology Value Fund LP filed an amended 13D. You can check out Biotechnology Value Fund LP's latest holdings and filings here. Arqule Inc ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
Etsy Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Apple Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Macy's, Inc. (M)
Vanguard Small Cap Value Index Fund 4.81M Dec 31, 2023 1.75% 89,121,520 Vanguard Extended Market Index Fund 4.05M Dec 31, 2023 1.47% 75,050,783 Avantis U.S. Small Cap Value Fund 3.32M Dec 31, 2023 ...
Nike Inc. Cl B
Under Armour Inc. Cl C 1.73% $2.87B Under Armour Inc. Cl A 1.82% $2.87B ...
Ennis, Inc. (EBF) Stock Price, News, Quote & History - Yahoo Finance
MIDLOTHIAN, Texas, March 25, 2024--Keith S. Walters, Chairman, President and Chief Executive Officer of Ennis, Inc. (NYSE: EBF), a manufacturer of business forms and other business products ...
Loading the latest forecasts...